Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial-Reference-Cited by-同舟云学术

Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

Published:2021-02 Issue:10273 Volume:397 Page:487-498
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Reich Kristian,Papp Kim A,Blauvelt Andrew,Langley Richard G,Armstrong April,Warren Richard B,Gordon Kenneth B,Merola Joseph F,Okubo Yukari,Madden Cynthia,Wang Maggie,Cioffi Christopher,Vanvoorden Veerle,Lebwohl Mark

Funder

UCB Pharma

Publisher

Elsevier BV

Subject

General Medicine

Reference27 articles.

1. Psoriasis;Boehncke;Lancet,2015

2. The psychosocial burden of psoriasis;Kimball;Am J Clin Dermatol,2005

3. Psoriasis: classical and emerging comorbidities;Oliveira;An Bras Dermatol,2015

4. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Sbidian;Cochrane Database Syst Rev,2020

5. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis;Gordon;N Engl J Med,2016

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality of reporting and concordance between sources of adverse events in the treatment of moderate-to-severe psoriasis: a cross-sectional study of RCTs from a Cochrane systematic review;Journal of Clinical Epidemiology;2024-09

2. Treatment strategies for Spondyloarthritis: Implementation of precision medicine – Or “one size fits all” concept?;Autoimmunity Reviews;2024-09

3. IL-17 and IL-23 Inhibitors Have the Fastest Time to Meaningful Clinical Response for Plaque Psoriasis: A Network Meta-Analysis;Journal of Clinical Medicine;2024-08-29

4. Efficacy and Safety of bimekizumab in elderly patients: real-world multicenter retrospective study – IL PSO (Italian Landscape Psoriasis);Journal of Dermatological Treatment;2024-08-20

5. Head-to-Head-Studien bei Psoriasis und Psoriasisarthritis;Zeitschrift für Rheumatologie;2024-08-14